Clinical Trials
25 trialsIbrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
National Cancer Institute (NCI)
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Vismodegib in Treating Patients With Advanced Chondrosarcomas
National Cancer Institute (NCI)
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
National Cancer Institute (NCI)
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
National Cancer Institute (NCI)
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
National Cancer Institute (NCI)
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction
National Cancer Institute (NCI)
Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
National Cancer Institute (NCI)
Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery
National Cancer Institute (NCI)
AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer
National Cancer Institute (NCI)
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Gamma-Secretase Inhibitor RO4929097 in Treating Patients With Metastatic or Unresectable Solid Malignancies
National Cancer Institute (NCI)
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
BMS-247550 in Treating Patients With Stage IV Melanoma
National Cancer Institute (NCI)
Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma
National Cancer Institute (NCI)
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck
National Cancer Institute (NCI)
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain
National Cancer Institute (NCI)
Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
National Cancer Institute (NCI)